DXC015

DXC015 is an investigational antibody-drug conjugate (ADC) developed by Hangzhou DAC Biotechnology, currently in preclinical development for the treatment of solid tumors. The drug is part of a broad portfolio of ADCs leveraging Hangzhou DAC's proprietary platform, which features a library of over 50 innovative linkers and several high-potency cytotoxic payloads, including tubulysin analogs and topoisomerase I inhibitors. Although the specific molecular target of DXC015 has not been publicly disclosed, the therapeutic candidate is engineered to provide targeted delivery of its cytotoxic payload to malignant cells, thereby enhancing efficacy while reducing off-target effects.